News
Mar 24, 2026
New AI Care Pathway combines AI echocardiography analysis with coordinated, guideline-based next steps for cardiology and heart failure teamsSAN FRANCISCO, CA –…
Mar 23, 2026
1 research study open to eligible peoplehATTR is a genetic condition where faulty transthyretin protein builds up as amyloid. UCSF is carrying out an observational…
Mar 23, 2026
AL amyloidosis is when abnormal proteins called light chains collect in organs. UCSF is studying a drug for people with relapsed or refractory multiple myeloma or…
Mar 23, 2026
a study on AL AmyloidosisAmyloidosisOpen-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120…
Mar 20, 2026
A 53-year-old male patient, previously diagnosed with genetic amyloidosis at Hanoi French Hospital in 2024, has successfully undergone a combined heart and liver…
Mar 19, 2026
Start dateThu, 03/19/2026 - 12:00End dateThu, 03/19/2026 - 12:00Venue - Full AddressKeble CollegeParks RoadOxfordOX1 3PGOrganiserBritish Society of Cardiovascular…
Mar 17, 2026
Eplontersen constitutes a promising improvement in the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR), according to a…
Mar 15, 2026
Amyloidosis is a group of protein-folding disorders characterized by the infiltration of multiple organs with amyloid deposits, primarily affecting the heart and…
Mar 13, 2026
AbstractPurpose of ReviewCardiac amyloidosis (CA) results from myocardial infiltration by misfolded amyloidogenic proteins and represents a heterogeneous group of…
Mar 13, 2026
Join us March 13-15, 2026, for the virtual Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis and Management.Led by Program Chair, Saurabh Malhotra, MD…